Evidence map›Paper›PMID 30222364›Full record

ArticleJournal of alternative and complementary medicine (New York, N.Y.)2019

Prospective Safety Evaluation of a Cardiovascular Health Dietary Supplement in Adults with Prehypertension and Stage I Hypertension.

Jennifer Joan Ryan, Douglas Allen Hanes, Jamie Corroon, Jan Taylor, Ryan Bradley

Open access · bronzeAbstract readClinical Study
In one paragraph

Article in Journal of alternative and complementary medicine (New York, N.Y.), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Trial
  2. Reserpine induced parkinsonism, a hidden threat of herbal medicine.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2023
    Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 2 countries.

Jennifer Joan Ryan1 Helfgott Research Institute, National University of Natural Medicine, Portland, OR.
Douglas Allen Hanes1 Helfgott Research Institute, National University of Natural Medicine, Portland, OR.
Jamie Corroon1 Helfgott Research Institute, National University of Natural Medicine, Portland, OR.
Jan Taylor1 Helfgott Research Institute, National University of Natural Medicine, Portland, OR.
Ryan Bradley1 Helfgott Research Institute, National University of Natural Medicine, Portland, OR.
National University of Natural Medicine · USUniversity of California, San Diego · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo prospectively examine the long-term safety of a cardiovascular health dietary supplement by assessing a comprehensive set of safety measures.

designSingle-arm, open-label study. LOCATION: National University of Natural Medicine, Portland, OR. SUBJECTS: Thirty adults with screening blood pressure readings consistent with prehypertension or stage I hypertension.

interventionOne caplet per day of a dietary supplement for 6 months. The investigated herbal-mineral supplement contains several ingredients, most notably Rauwolfia serpentina. OUTCOME MEASURES: Primary measures included b-type natriuretic peptide (NT-proBNP), aspartate aminotransferase (AST), alanine aminotransferase (ALT), estimated glomerular filtration rate (eGFR), electrolytes, and the Patient Health Questionnaire (PHQ-9). Exploratory measures included physical vital signs, cholesterol levels, high-sensitivity cardiac troponin-I, cystatin C, endothelin, interleukin (IL)-6, IL-17a, tumor necrosis factor-α, high-sensitivity C-reactive protein, blood counts, and the Patient Reported Outcome Measure Information System (PROMIS) Sleep Disturbance Short Form 8b.

resultsNT-proBNP, AST, ALT, eGFR, sodium, calcium, magnesium, PHQ-9 score, and the majority of exploratory measures did not change. However, serum potassium increased (p < 0.05), systolic blood pressure decreased (p < 0.0001), and diastolic blood pressure decreased (p < 0.0001). There were no serious adverse events, but 30% of participants withdrew citing potential side effects, most commonly nasal congestion or fatigue; most participants who reported nasal congestion also reported concomitant seasonal allergies. Adherence to the supplement was 90.9%.

conclusionsThe findings of this study suggest that the investigated dietary supplement is safe for long-term use in adults with prehypertension and stage I hypertension. Additional results of this study, particularly the increase in serum potassium and decreases in systolic and diastolic blood pressure, are promising and suggest that future research on this dietary supplement, or its ingredients, should further explore effects on blood pressure and biologic mechanisms of action, which may involve potassium-sparing and diuretic effects.

Indexed as

AdultAntihypertensive AgentsBlood PressureCytokinesDietary SupplementsFemaleHumansHypertensionLipidsMaleMiddle AgedPrehypertensionProspective StudiesAntihypertensive AgentsCytokinesLipidscardiovascular healthdietary supplementshypertensionprehypertensionsafetytolerability

Identifiers

PMID30222364
PMCPMC6389760
OpenAlexW2890553762

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.